Xilio Therapeutics
33 hedge funds and large institutions have $9.1M invested in Xilio Therapeutics in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
10% more funds holding
Funds holding: 30 → 33 (+3)
0.18% more ownership
Funds ownership: 4.11% → 4.29% (+0.18%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
73% less capital invested
Capital invested by funds: $33.5M → $9.1M (-$24.4M)
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$322K |
| 2 |
Renaissance Technologies
New York
|
+$267K |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$118K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$72.6K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$63.6K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DF
26
Dunhill Financial
London,
United Kingdom
| $5.65K | +$14.5K | +734 | New |
|
27
JP Morgan Chase
New York
| $1.57K | +$198 | +10 | +5% |
|
|
KFI
28
Key Financial Inc
West Chester,
Pennsylvania
| $456 | – | – | – |
|
29
UBS Group
Zurich,
Switzerland
| $111 | – | – | – |
|
30
Wells Fargo
San Francisco,
California
| $58 | +$20 | +1 | +14% |
|
|
CFB
31
Cullen/Frost Bankers
San Antonio,
Texas
| $55 | – | – | – |
|
32
Bank of America
Charlotte,
North Carolina
| $6 | -$320K | -16,193 | -100% |
|
33
Qube Research & Technologies (QRT)
London,
United Kingdom
| $2 | – | – | – |
|
|
HMC
34
Harvard Management Company
Boston,
Massachusetts
| – | -$878K | -29,719 | Closed |
|
|
SCM
35
Soleus Capital Management
Greenwich,
Connecticut
| – | -$479K | -16,210 | Closed |
|
36
Dimensional Fund Advisors
Austin,
Texas
| – | -$55.8K | -1,889 | Closed |
|
37
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$158 | +8 | +32% |
|
XLO Hedge Fund Activity: Q4 2023 in Review
33 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Xilio Therapeutics (XLO) for Q4 2023, worth a combined $9.1M — down 73% from $33.5M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new XLO positions and 3 closed out — a net gain of 3 holders — while 8 added to existing stakes and 4 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $322K. The largest seller was Harvard Management Company, exiting entirely with an estimated $878K sold.
- 33 institutional investors held Xilio Therapeutics (XLO) as of Q4 2023, up from 30 in Q3 2023.
- Funds reported $9.1M of Xilio Therapeutics stock for Q4 2023, down 73% quarter-over-quarter.
- 6 funds opened new Xilio Therapeutics positions in Q4 2023 and 3 closed out, a net change of +3 holders.
- The largest Xilio Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $322K added.
- The largest Xilio Therapeutics seller in Q4 2023 was Harvard Management Company, an estimated $878K sold.
Based on aggregated 13F filings for Q4 2023.